Clinical trials: Zoledronic acid, completed
Osteoporosis
1 Year Open-label Extension to CZOL446H2337 Safety and Efficacy Trial of Zoledronic Acid Twice Yearly in Osteoporotic Children Treated With Glucocorticoids
This 1-year open-label extension to CZOL446H2337 is designed to evaluate the safety and efficacy of zoledronic acid twice yearly in osteoporotic children treated with glucocorticoids.
- Trial name
- NCT01197300
- Testing
- Zoledronic acid
- Where
- 10 sites in Australia, Canada and 4 more
- Volunteers
- 25 people
- Sponsor
- Novartis Pharmaceuticals
Osteopenia
To Assess the Efficacy of Over-the-counter Analgesics in the Prevention/Treatment of Transient Post-dose Symptoms Following Zoledronate Infusion in Post-menopausal Women
Zoledronic acid is a medicine being studied in people with low bone mass. Side effects such as headache, fever, muscle aches, and pains, may occur following the infusion.
- Trial name
- NCT00145275
- Testing
- zoledronic acid
- Where
- 10 sites in United States, Australia and 3 more
- Volunteers
- 455 people
- Sponsor
- Novartis
Bone Metastases in Men With Hormone-Refractory Prostate Cancer, Bone Metastases in Subjects With Advanced Breast Cancer
Open Label Extension to SRE Studies in United Kingdom and Czech Republic Only
The purpose of this study is to describe the safety and tolerability of denosumab administration as measured by adverse events, immunogenicity, and safety laboratory parameters in subjects who previously received either…
- Conditions
- Bone Metastases in Men With Hormone-Refractory Prostate Cancer, Bone Metastases in Subjects With Advanced Breast Cancer, Bone Metastases in Subjects With Advanced Cancer or Multiple Myeloma
- Trial name
- NCT00950911
- Testing
- amg 162
- Where
- 17 sites in Czechia, United Kingdom
- Volunteers
- 35 people
- Sponsor
- Amgen
Renal Osteodystrophy
Zoledronic Acid to Prevent Bone Loss After Kidney Transplantation
The purpose of this study is to determine whether zolendronic acid, a third generation bisphosphonate, is effective in preventing bone loss in the first year after kidney transplantation.
- Trial name
- NCT01675089
- Testing
- Zoledronic acid
- Where
- Brazil
- Volunteers
- 34 people
- Sponsor
- University of Sao Paulo General Hospital
Neoplasm Metastasis
Assessment of Pain and Quality of Life in Breast and Prostate Cancer Patients With Bone Metastases
This study will evaluate the safety, tolerability and efficacy of zoledronic acid administered intravenously every 3-4 weeks in patients with bone metastases from either breast cancer or prostate cancer.
- Trial name
- NCT00434317
- Testing
- Zoledronic acid
- Where
- 4 sites in Hungary
- Volunteers
- 80 people
- Sponsor
- Novartis
Prostate Cancer
Evaluation of Bone Markers as Diagnostic Tools for Early Detection of Bone Metastases in Patients With High Risk Prostate Cancer
It is the aim of this prospective, single-group, clinical study to assess whether bone parameters can be used as diagnostic tools for early detection of bone metastases in patients with high risk prostate cancer.
- Trial name
- NCT00391690
- Testing
- Zoledronic acid
- Where
- Germany
- Volunteers
- 99 people
- Sponsor
- Novartis
Bone Marrow Edema
Assessment of Efficacy of Zoledronic Acid in the Treatment of Bone Marrow Edema Syndrome
The primary aim is to test the reduction of bone marrow edema syndrome after a singular intravenous treatment with Zoledronic Acid within 6 weeks compared to placebo.
- Trial name
- ZoMARS (NCT01348269)
- Testing
- Aclasta
- Where
- 2 sites in Germany
- Volunteers
- 48 people
- Sponsor
- Wuerzburg University Hospital
Breast Cancer
Investigating the Biological Effects of the Addition of Zoledronic Acid to Pre-operative Chemotherapy in Breast Cancer
There is clear preclinical in vitro and in vivo evidence of sequence dependent synergy between chemotherapy agents and zoledronic acid.
- Trial name
- ANZAC (NCT00525759)
- Testing
- 5-FU, Epirubicin, Cyclophosphamide, Docetaxel, 5-FU, Epirubicin, Cyclophosphamide, Docetaxel, Zoledronic acid
- Where
- United Kingdom
- Volunteers
- 40 people
- Sponsor
- Sheffield Teaching Hospitals NHS Foundation Trust
Osteoporosis
Efficacy and Safety of Zoledronic Acid for the Treatment of Osteoporosis in Men
The goal of this study is to determine the effectiveness and safety of an annual intravenous treatment of zoledronic acid for the treatment of osteoporosis in men. All patients will receive calcium and vitamin D supplements.
- Trial name
- NCT00097825
- Testing
- Zoledronic Acid
- Where
- 26 sites in United States, Australia and 1 more
- Volunteers
- 288 people
- Sponsor
- Novartis Pharmaceuticals
Hematopoietic Stem Cell Transplantation
Zoledronic Acid in Combination With Interleukin-2 to Expand Vγ9Vδ2 T Cells After T-replete Haplo-identical Allotransplant
Patients receiving haplo-SCT are at high-risk of relapse. Vγ9Vδ2 T cells exhibit is a well-known population able to exert cytotoxicity toward a large range of tumor in vitro or in vivo.
- Trial name
- HILDEGAZ (NCT03862833)
- Testing
- IL2, Zoledronic Acid
- Where
- France
- Volunteers
- 30 people
- Sponsor
- Nantes University Hospital
Breast Neoplasms
Simultaneous Study of Gemcitabine-Docetaxel Combination Adjuvant Treatment, as Well as Extended Bisphosphonate and Surveillance-Trial
This is an open-label, multicenter, 2x2 factorial design, randomized controlled, Phase III study comparing the disease free survival after randomisation in patients treated with 3 cycles of…
- Trial name
- NCT02181101
- Testing
- FEC-DocGemzar adjuvant chemotherapy, FEC-Doc adjuvant chemotherapy, Zoledronic acid i.v. 2 years
- Where
- Germany
- Volunteers
- 3,754 people
- Sponsor
- Ludwig-Maximilians - University of Munich
Breast Cancer With Metastatic Bone Disease
Study Comparing Full-dose Radiotherapy Versus Reduced Dose in the Management of Bone Metastasis in Patients With Breast Cancer Receiving Zoledronic Acid
The aim of this prospective, randomized, open-label, multicentric clinical study is to assess the effícacy and tolerability of zoledronic acid 4 mg IV infused over 15 minutes every 4 weeks for a total of 6 infusions, in…
- Trial name
- NCT00172029
- Testing
- Zoledronic acid
- Where
- 7 sites in Turkey (Türkiye)
- Volunteers
- 116 people
- Sponsor
- Novartis
Myelofibrosis, Myeloid Metaplasia
A Trial of Zoledronic Acid in Patients With Myelofibrosis With Myeloid Metaplasia (MMM)
In this trial, the question is addressed if zoledronic acid (Zometa, Novartis Pharma)could be of clinical benefit for patients with myelofibrosis and myeloid metaplasia (MMM).
- Trial name
- NCT00287261
- Testing
- zoledronic acid
- Where
- 6 sites in Australia, Belgium and 4 more
- Volunteers
- 17 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Prostate Cancer
PET Scanning to Evaluate Zoledronate Efficacy in Metastatic Prostate Cancer
The primary goal for this trial is to assess the change in PET scans with the administration of zoledronate (bisphosphonate) therapy in patients with metastatic prostate cancer.
- Trial name
- NCT01205646
- Testing
- zoledronate therapy, PET Scan
- Where
- 2 sites in United States
- Volunteers
- 11 people
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Osteogenesis Imperfecta, Type I, Osteogenesis Imperfecta Type III
A Study in Adult Patients With Type I, III or IV Osteogenesis Imperfecta Treated With BPS804
The purpose of this study is to select a suitable dose of BPS804 by measuring the strength/quality of bone using a special type of CT scanner. Participants will be treated for 12 months and followed up for a further 12 months.
- Conditions
- Osteogenesis Imperfecta, Type I, Osteogenesis Imperfecta Type III, Osteogenesis Imperfecta Type IV
- Trial name
- Asteroid (NCT03118570)
- Testing
- setrusumab, Calcium, Vitamin D
- Where
- 25 sites in United States, Canada and 3 more
- Volunteers
- 112 people
- Sponsor
- Ultragenyx Pharmaceutical Inc
Osteogenesis Imperfecta
Treatment of Osteogenesis Imperfecta With Parathyroid Hormone and Zoledronic Acid
Osteogenesis imperfecta (OI) is an inherited skeletal disorder characterised by increased risk of fragility fractures. Bisphosphonates are frequently prescribed for adult patients with OI with the aim of preventing fractures but…
- Trial name
- TOPaZ (NCT03735537)
- Testing
- Teriparatide Pen Injector, Zoledronic Acid
- Where
- 23 sites in Ireland, United Kingdom
- Volunteers
- 350 people
- Sponsor
- University of Edinburgh
Osteonecrosis of the Jaw, Infection Leading to Hospitalization
Osteonecrosis of the Jaw (ONJ) and Infection Among Nordic Cancer Patients Treated With XGEVA™ or Zoledronic Acid
A non-interventional study to assess incident rates of Osteonecrosis of the Jaw and Infections leading to hospitalization in Cancer patients treated with XGEVA™ in Sweden, Denmark and Norway.
- Trial name
- NCT01967160
- Volunteers
- 2,560 people
- Sponsor
- Amgen
Healthy Postmenopausal Women
Open Label Dose Escalation Phase I Study to Investigate the Safety and Pharmacokinetics of T121E01F and T121E02F in Healthy Postmenopausal Women
THAR2011-1 is a Phase I, single dose, open-label dose-escalation study to determine the safety, absolute bioavailability, dose proportionality, and pharmacokinetics of T121 in healthy postmenopausal women.
- Trial name
- NCT01721993
- Testing
- T121, Zoledronic acid
- Where
- United States
- Volunteers
- 71 people, healthy volunteers welcome
- Sponsor
- Thar Pharmaceuticals, Inc
Bariatric Surgery Candidate, Bone Loss
Healthy Body, Healthy Bones After Bariatric Surgery Trial
One in three adults in the United States suffers from obesity. Bariatric surgery is an increasingly utilized and effective treatment for obesity and obesity-related comorbidities, however, the massive weight loss associated with…
- Conditions
- Bariatric Surgery Candidate, Bone Loss, Bone Resorption
- Trial name
- NCT04279392
- Testing
- Zoledronic Acid 5 mg/Bag 100 ml Inj
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- University of Nebraska
Osteoporosis
A Clinical Trial to Evaluate Efficacy of Once or Twice ZOledronic Acid After Different Duration of denOsumMab Administration in Postmenopausal Women With Osteoporosis (ZOOM Study)
Denosumab(Dmab) is a monoclonal antibody that inhibits the receptor-activator of nuclear factor kappa-B ligand. It improves bone density and reduces fractures by inhibiting osteoclast recruitment and differentiation.
- Trial name
- NCT05361408
- Testing
- Zoledronic acid, once, Zoledronic acid, twice
- Where
- South Korea
- Volunteers
- 114 people
- Sponsor
- Yonsei University